About Novacea
Novacea is a Healthcare company based in Richmond (United States) founded in 2001, and was acquired by Transcept Pharmaceuticals in September 2008. Serotonin inhibitor drugs for cancer are developed by Novacea. Novacea has raised $35 million across 1 funding round from investors including Apax Partners, Transcept Pharmaceuticals and Domain Associates. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Novacea Pharmaceuticals was established in 2001 in Richmond, United States, within the biotechnology sector. Focus was placed on in-licensing and advancing cancer therapies, including Asentar in phase 3 trials for androgen-independent prostate cancer and phase 2 for advanced pancreatic cancer, as well as AQ4N in phase 1b2a trials for glioblastoma multiforme. Acquisition by Transcept Pharmaceuticals occurred in September 2008, leading to a merger.
- Headquarters Richmond, United States
- Stage Public
- SectorsHealthcare
- Website novacea.com
- Social LinkedIn
- Acquired by Transcept Pharmaceuticals (Sep 2008)
- Total Equity Funding$35M (USD)
in 1 rounds
- Latest Funding Round$35M (USD), Series C
Jan 2004
- InvestorsApax Partners
& 6 more
- Acquired byTranscept Pharmaceuticals
(Sep 2008)
Funding Insights of Novacea
Novacea has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series C round of $35 million completed in January 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35M
- Total Rounds 1
- Last Round Series C β $35M
- First Round $35M
(Jan 2004)
- Investors Count 6
All 1 funding rounds of Novacea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2004 | $35M | Series C | β | β |
7 investors in total: 7 institutional.
Investors in Novacea
Novacea has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Apax Partners, Transcept Pharmaceuticals and Domain Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
| proquestvc.com | ||||
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions | 1996 | transcept.com | Boston, United States |
Investor details for Novacea
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Novacea
4 dated milestones of Novacea across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Novacea is founded.
- Funding First funding round of $35.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Transcept Pharmaceuticals.
Competitors of Novacea
Novacea has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Novacea
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Novacea
Websites that share an audience with Novacea (novacea.com).
Websites whose visitors overlap most with Novacea. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mundipharma.net | mundipharma.net | 100% | β | ||
| cap-m-quik.com | 100% | View details | |||
| ventanamed.com | 100% | View details | |||
canderm.com | canderm.com | 100% | β | ||
| viropharma.com | 100% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Novacea
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Novacea (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novacea
Complete news archive for Novacea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novacea
Novacea was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Novacea is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.
Novacea is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series C of $35M, raised on Jan 2004.
Novacea Pharmaceuticals was established in 2001 in Richmond, United States, within the biotechnology sector. Focus was placed on in-licensing and advancing cancer therapies, including Asentar in phase 3 trials for androgen-independent prostate cancer and phase 2 for advanced pancreatic cancer, as well as AQ4N in phase 1b2a trials for glioblastoma multiforme. Acquisition by Transcept Pharmaceuticals occurred in September 2008, leading to a merger.
Novacea's top competitors include C4 Therapeutics, Erasca and MiRagen.
Novacea has 7 investors. Key investors include Apax Partners, Transcept Pharmaceuticals, Domain Associates, NEA, and Versant Ventures.
Yes. Novacea was acquired by Transcept Pharmaceuticals in September 2008.

